The incidence of several types of chronic and acute pain will increase significantly over the next few years, driving growth in transdermal pain products to reach $9.2 billion in 2015, according to a study by Greystone Research Associates.
According to George Perros, Greystone Research Managing Director, evolution in pain management guidelines and a better appreciation for pain-associated morbidity by clinicians are making pain management more essential for patients. Greystone's study, "Transdermal Pain Management to 2015," analyses commercial transdermal prescription drug products and development-stage candidates, as well as examining key factors influencing market demand and shaping growth prospects.
Read the Greystone Research Associates press release on transdermal pain products.
According to George Perros, Greystone Research Managing Director, evolution in pain management guidelines and a better appreciation for pain-associated morbidity by clinicians are making pain management more essential for patients. Greystone's study, "Transdermal Pain Management to 2015," analyses commercial transdermal prescription drug products and development-stage candidates, as well as examining key factors influencing market demand and shaping growth prospects.
Read the Greystone Research Associates press release on transdermal pain products.